FGM | LA | RR | Total | |
---|---|---|---|---|
N (%) | 122 (18.2) | 125 (18.7) | 422 (61.3) | 669 |
Age | ||||
≤ 5 years (%) | 23 (18.8) | 24 (19.2) | 138 (32.7) | 185 (27.7) |
≥ 5 to 18 years (%) | 80 (65.6) | 58 (46.4) | 208 (49.3) | 346 (51.7) |
Adults (> 18 years) (%) | 19 (15.6) | 43 (34.4) | 76 (18.0) | 138 (20.6) |
pfcrt-PCR positivity (%) | 109 (18.6) | 108 (18.5) | 368 (62.9) | 585 |
CQ-sensitive (CVMNK) only (%) | 21 (19.3) | 37 (34.3) | 68 (18.5) | 126 (21.6) |
CQ-resistance 1 (CVIET) only (%) | 43 (39.4) | 50 (46.3) | 174 (47.3) | 267 (45.6) |
CQ-resistance 2 (SVMNT) (%) | 0 | 0 | 0 | 0 |
Mix (R and S) (%) | 45 (41.3) | 21 (19.4) | 126 (34.2) | 192 (32.8) |
msp1 PCR positivity (%) | 111 (18.7) | 107 (18.1) | 374 (63.2) | 592 |
Monoclonal infection | 24 (21.6) | 43 (40.2) | 96 (25.7) | 163 (27.5) |
Polyclonal infection | 87 (78.4) | 64 (59.8) | 278 (74.3) | 429 (72.5) |
K1 only | 18 | 40 | 88 | 146 |
MAD20 only | 10 | 15 | 31 | 56 |
RO33 only | 11 | 14 | 39 | 64 |
K1 + MAD20 | 14 | 10 | 61 | 85 |
K1 + RO33 | 24 | 17 | 66 | 107 |
MAD20 + RO33 | 8 | 4 | 14 | 26 |
K1 + MAD20 + RO33 | 26 | 7 | 75 | 108 |